Should I buy CME Group (CME) stock or is it too late?

CME Group · Financials · price $281

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: Piper Sandler — 71% of its targets hit on this sector (413 calls tested). It aims for $295 (+5.0 %), call made on July 16, 2026, maturing on July 16, 2027 (43 d ago).

The 10 reliable analysts $270-3.9 %

The 1 other firm $323+15 %

How to read it: the 10 reliable firms are not filtered by optimism — 4 aim above the price, 6 below, hence their $270 median. “The 1 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on CME Group

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Piper Sandler	89 %	+22.1 %	9	$295 +5%
Deutsche Bank	69 %	+12.8 %	29	$270 -4%
Citigroup	76 %	+11.6 %	17	$300 +7%
Barclays	88 %	+11.6 %	8	$270 -4%
UBS	75 %	+8.1 %	16	$260 -7%
Oppenheimer	64 %	+7.6 %	14	$303 +8%
B of A Securities	33 %	-3.8 %	6	$230 -18%
Raymond James	29 %	-9.0 %	7	$320 +14%

In short — Should you invest in CME Group? Is it too late, still worth it? Analysts are split (46% buy, median target $270, i.e. -4%), and the most reliable on CME targets even higher. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

The most reliable firm on CME, Morgan Stanley (100% hit rate, 2 scored calls), targets $330 (call made on July 23, 2026, maturing on July 23, 2027) (+17%) in its most recent call, and $312 (call made on October 1, 2025, maturing on October 1, 2026) (+11%) in the one coming due soonest.
Pays a dividend (4.9% yield), raised for 6 years — regular income on top of potential upside.

⚠️ Reasons to hesitate

The consensus is not unanimous: of 13 ratings, 5 are neutral and 2 are sells.
Limited upside: the median target is only -4% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.

The analyst consensus on CME

Median target $270 (-4%) · 13 ratings · Hold consensus

Strong Buy00%

Buy646%

Hold538%

Sell215%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in CME Group now?

We won't decide for you. The facts: 46% of analysts rate it a buy, median target $270 (-4%), and Morgan Stanley (most reliable on CME, 100%) targets $330. Weigh that against valuation (P/E ~24). This is not personalized advice.

Is it too late to invest in CME Group?

The stated upside is small: the median target ($270) sits just -4% from the price ($281) (most reliable on CME: Morgan Stanley, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is CME Group still worth investing in?

It depends on the gap between the price ($281) and its estimated value: analysts target $270 on median (-4%), with 46% buys (most reliable on CME: Morgan Stanley, 100%). Cross-check with their real reliability on CME and the cautions above. Information, not advice.

What's the main risk in buying CME?

The consensus is not unanimous: of 13 ratings, 5 are neutral and 2 are sells.

→ Go deeper: the full CME Group profile (consensus, analyst reliability, price target, performance).